MicroTransponder Announces Positive Medicare Payment Change for Vivistim® Procedure
Effective January 1, 2026, the Vivistim® procedure is assigned to New Technology Ambulatory Payment Classification 1580, with an associated national average payment of approximately $45,000 MicroTransponder®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim® Paired VNS™ Systemfor chronic stroke recovery, today announced that the Centers for Medicare and Medicaid Services (CMS) […]